{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:24Z","timestamp":1793824644337,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009275","name":"DeGregorio Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Parker Institute of Cancer Immunotherapy Torrey Coast The Lavine Family","id":[{"id":"https:\/\/ror.org\/0184qbg02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65148-6","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:54Z","timestamp":1761991314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies"],"prefix":"10.1038","volume":"16","author":[{"given":"Elizabeth J.","family":"Carstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3348-3860","authenticated-orcid":false,"given":"Kazuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"De Vizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar Khoshtinat","family":"Nikkhoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mangipudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canh Hiep","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tate","family":"Weltzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lile","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-7734","authenticated-orcid":false,"given":"Anusuya","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-7407","authenticated-orcid":false,"given":"Jonathan A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-6203","authenticated-orcid":false,"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7587","authenticated-orcid":false,"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"65148_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"65148_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer 149, 778\u2013789 (2021).","journal-title":"Int. J. Cancer"},{"key":"65148_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"65148_CR4","doi-asserted-by":"publisher","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","volume":"35","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma. Ann. Oncol. 35, S877\u2013S878 (2024).","journal-title":"Ann. Oncol."},{"key":"65148_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J. Clin. Oncol. 42, 2012\u20132020 (2024).","journal-title":"J. Clin. Oncol."},{"key":"65148_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-50600-8","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi, E., Shin, J., Ryu, M. H., Kim, H. D. & Park, Y. S. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci. Rep. 14, 1\u20139 (2024).","journal-title":"Sci. Rep."},{"key":"65148_CR7","doi-asserted-by":"crossref","unstructured":"Klempner, S. J., Janjigian, Y. Y. & Wainberg, Z. A. Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas. ESMO Open 8, 100778 (2023).","DOI":"10.1016\/j.esmoop.2022.100778"},{"key":"65148_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27, 1058 (2024).","journal-title":"Gastric Cancer"},{"key":"65148_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim, H. D. et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci. Rep. 13, 20047 (2023).","journal-title":"Sci. Rep."},{"key":"65148_CR10","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi, T. et al. claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol. Cell. Biol. 21, 7380\u20137390 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"65148_CR11","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 Splice Variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"65148_CR12","doi-asserted-by":"publisher","first-page":"e1523096","DOI":"10.1080\/2162402X.2018.1523096","volume":"8","author":"\u04e6 T\u00fcreci","year":"2018","unstructured":"T\u00fcreci, \u04e6, Mitnacht-Kraus, R., W\u00f6ll, S., Yamada, T. & Sahin, U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8, e1523096 (2018).","journal-title":"Oncoimmunology"},{"key":"65148_CR13","first-page":"3665","volume":"19","author":"V Moentenich","year":"2020","unstructured":"Moentenich, V. et al. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol. Lett. 19, 3665 (2020).","journal-title":"Oncol. Lett."},{"key":"65148_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00428-024-03756-1","volume":"485","author":"P Wagner","year":"2024","unstructured":"Wagner, P. et al. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes. Virchows Arch. 485, 63 (2024).","journal-title":"Virchows Arch."},{"key":"65148_CR15","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke, P. et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int. J. Cancer 135, 2206\u20132214 (2014).","journal-title":"Int. J. Cancer"},{"key":"65148_CR16","doi-asserted-by":"crossref","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"65148_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"65148_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N. Engl. J. Med. 391, 1159\u20131162 (2024).","journal-title":"N. Engl. J. Med."},{"key":"65148_CR19","doi-asserted-by":"publisher","first-page":"1371421","DOI":"10.3389\/fonc.2024.1371421","volume":"14","author":"Q Xu","year":"2024","unstructured":"Xu, Q., Jia, C., Ou, Y., Zeng, C. & Jia, Y. Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer. Front. Oncol. 14, 1371421 (2024).","journal-title":"Front. Oncol."},{"key":"65148_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep. Med. 5, 101710 (2024).","journal-title":"Cell Rep. Med."},{"key":"65148_CR21","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"65148_CR22","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2022.40.16_suppl.2538","volume":"40","author":"GP Botta","year":"2022","unstructured":"Botta, G. P. et al. Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. J. Clin. Oncol. 40, 2538\u20132538 (2022).","journal-title":"J. Clin. Oncol."},{"key":"65148_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.  Lancet 405, 2049\u20132060 (2025).","journal-title":"Lancet"},{"key":"65148_CR24","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2025.43.16_suppl.4022","volume":"43","author":"DB Zhen","year":"2025","unstructured":"Zhen, D. B. et al. Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2\u2013targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma. J. Clin. Oncol. 43, 4022\u20134022 (2025).","journal-title":"J. Clin. Oncol."},{"key":"65148_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"\u00d6 T\u00fcreci","year":"2011","unstructured":"T\u00fcreci, \u00d6 et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481, 83\u201392 (2011).","journal-title":"Gene"},{"key":"65148_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang, H. et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J. Natl. Cancer Inst. 111, 409\u2013418 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"65148_CR27","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1096\/fj.201800636R","volume":"33","author":"MA Brehm","year":"2019","unstructured":"Brehm, M. A. et al. Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.  FASEB J. 33, 3137\u20133151 (2019).","journal-title":"FASEB J."},{"key":"65148_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/cancers16030679","volume":"16","author":"MC Mathias-Machado","year":"2024","unstructured":"Mathias-Machado, M. C. et al. Claudin 18.2 as a New Biomarker in Gastric Cancer\u2014What Should We Know? Cancers 16, 679 (2024).","journal-title":"Cancers"},{"key":"65148_CR29","doi-asserted-by":"publisher","first-page":"232393","DOI":"10.3389\/fimmu.2016.00619","volume":"7","author":"D Drabek","year":"2016","unstructured":"Drabek, D. et al. Expression cloning and production of human heavy-chain-only antibodies from murine transgenic plasma cells. Front. Immunol. 7, 232393 (2016).","journal-title":"Front. Immunol."},{"key":"65148_CR30","unstructured":"Birocchi, F. et al. On-target off-tumor toxicity of Claudin18.2-directed CAR-T cells in preclinical models. Nat. Commun. (2025)."},{"key":"65148_CR31","doi-asserted-by":"publisher","first-page":"1032403","DOI":"10.3389\/fimmu.2022.1032403","volume":"13","author":"R Mao","year":"2022","unstructured":"Mao, R., Kong, W. & He, Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front. Immunol. 13, 1032403 (2022).","journal-title":"Front. Immunol."},{"key":"65148_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507 (2023).","journal-title":"Nature"},{"key":"65148_CR33","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41, 1871\u20131891.e6 (2023).","journal-title":"Cancer Cell"},{"key":"65148_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419\u2013432.e16 (2016).","journal-title":"Cell"},{"key":"65148_CR35","doi-asserted-by":"crossref","unstructured":"Smith, E. L. et al. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. Mol. Ther. 26, 1447\u20131456 (2018).","DOI":"10.1016\/j.ymthe.2018.03.016"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65148-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65148-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65148-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:56Z","timestamp":1761991316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65148-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65148"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65148-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.L.S. has consulted for ArsenalBio, Blackstone Life Sciences, Chroma Medicine, Clade Therapeutics, Eureka Therapeutics, ImmuneBridge, Legend Biotech, Overland Pharmaceuticals, Predicta Biosciences, and Sana Biotech. E.L.S. holds equity in Predicta Biosciences and receives research funding from Sanofi. E.L.S. is an inventor on licensed patents regarding CAR T cells and antibodies to treat multiple myeloma and received royalties from Bristol Myers Squibb and Sanofi. E.L.S. was on a Scientific Advisory Board for Bristol Myers Squibb, Chimeric Therapeutics, Novartis, and Sanofi. S.J.K has served a consultant\/advisory role for Bristol Myers Squibb, Merck, Eli Lilly, Roche, Astellas, Daiichi Sankyo, Pieris, Natera, Novartis, AstraZeneca, Mersana, Sanofi-Aventis, Taiho Oncology, Eisai, and I-Mab Therapeutics. J.A.N. serves as a consultant for Leica Biosystems. A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Inc., Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, Taiho Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures, and Ventus Therapeutics. A.J.A. holds equity in Riva Therapeutics and Kestrel Therapeutics. A.J.A. has received research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Nimbus Therapeutics, Novartis, Novo Ventures, Revolution Medicines, and Syros Pharmaceuticals. K.S. reports receiving fees for consulting and advisory roles from Bristol Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology Inc, Bayer, GlaxoSmithKline, HEALIOS, Moderna Inc, Arcus Biosciences Inc; receiving honoraria from Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Ono Pharmaceutical, and Astellas. K.S. has research funding from Merck Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Ono Pharmaceutical, Astellas, Eisai, Amgen, PRA Health Sciences, AstraZeneca, PPD-SNBL K.K., and TORAY. I.N. receives research funding from Astellas, Ono Pharmaceutical Co., Ltd., Merck Sharp & Dohme (MSD), Daiichi Sankyo, Boehringer Ingelheim, and Chugai Pharmaceutical Co., Ltd. Honoria from Astellas, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Merck Sharp & Dohme (MSD), Daiichi Sankyo, and Chugai Pharmaceutical Co., Ltd. N.S. received lecture fees from Astellas. A.R. has consulted for Black Opal Ventures (BOV). Q.L., J.Z., C.N., C.D., X.W., and L.L. are employees of Nona Biosciences (Suzhou) Co., Ltd.; E.L.S., E.J.C., A.R., Q.L., J.Z., C.N., C.D., X.W., and L.L. are inventors on the patent CLDN18 VH CAR, App. No. 202510028444.4 related to this work. K.T., M.D.V., M.M., S.K.N., A.M., C.H.N., and T.W. do not report any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9651"}}